Approximately three-quarters of patients in both studies had stage 1 cancer, and recurrence patterns, including timing and sites of recurrence, among those with EGFR-positive NSCLC relative to those with wildtype EGFR have not been well characterized. The gene discussed is EGFR; the disease is cancer.